Objective: To assess the use of epilepsy surgery in patients with medically intractable epilepsy in a publicly funded universal health care system.
In Canada, 1 in every 200 people has epilepsy. 1 Seizure drugs prevent ongoing seizures in most (70%) patients with epilepsy. 2, 3 Medically intractable epilepsy is a term coined by the International League Against Epilepsy (ILAE) to define a group of patients who do not respond to treatment with seizure drugs for a reasonable period of time. 4 Epilepsy surgery should be considered in such patients. 5 Since the 1950s, epilepsy surgery has been the treatment of choice for patients not responding to treatment with seizure drugs. In 2001, a team of Canadians performed the first randomized controlled trial of surgery for temporal lobe epilepsy, the most common type of medically intractable epilepsy. In this trial, the benefit of epilepsy surgery was found to be significantly better than the continuation of seizure drugs, not only with regards to seizure control, but also in terms of quality of life. 6 A subsequent trial in the United States confirmed these findings, 7 prompting the American Academy of Neurology to publish a practice parameter recommending epilepsy surgery in patients with focal epilepsy who do not respond to seizure drugs. 8 In spite of the increasing evidence and introduction of a new practice parameter, candidate patients continue to wait years to see a specialist and particularly to be assessed in an epilepsy surgery program. 5 Even with the publication of a Canadian tool to determine the appropriateness for a referral to an epilepsy surgery program, 9 there is uncertainty as to whether referral patterns have changed. Furthermore, the ILAE through a special task force found that epilepsy surgery is underutilized in North America, despite the existence of many comprehensive epilepsy surgery programs in Canada and the United States. 10 To better understand the current practices in Canada, we assessed the rate of epilepsy surgery in patients with medically intractable epilepsy using large population-based databases in Ontario. To further determine possible inequalities in access, we additionally identified patient predictors associated with no surgery.
METHODS Study design. Ontario is the most populous province in Canada, with approximately 13 million residents (2012 population estimate: 13,505,900). All residents have universal access to hospital care and physician services, while eligible residents (including those aged 65 years or older, on social assistance, receiving home care, in long-term care, or eligible for the special drugs program 11 ) have additional universal prescription drug coverage of more than 3,800 medications when purchasing within the province. 12 These health care encounters are recorded in population-based, linkable databases that are held at the Institute for Clinical and Evaluative Sciences (ICES). We conducted a retrospective, population-based cohort study of patients with medically intractable epilepsy from January 1, 2001, to December 31, 2010, using these linked health care databases in Ontario, Canada.
Standard protocol approvals, registrations, and patient consents. The reporting of this study followed guidelines for observational studies. 13 The study was approved by the Sunnybrook Health Science Centre Research Ethics Board in Toronto, Ontario, Canada.
Data sources. We identified our cohort of patients, their characteristics, and outcomes using 6 data sources: the Ontario Health Insurance Plan (OHIP), which includes information for inpatient and outpatient fee-for-service physician claims; the Registered Persons Database (RPDB), which contains vital statistics on all permanent residents of Ontario; the National Ambulatory Care Reporting System (NARCS) and the Canadian Institute for Health Information Discharge Abstract Database (CIHI-DAD), which provide diagnostic and procedural information on all hospitalizations and emergency room visits using the ICD-9 (prior to April 2002) and ICD-10 (after April 2002) coding systems; and the Ontario Drug Benefits (ODB) database, which provides information on prescription drug use for eligible patients of all ages. This latter data source contains highly accurate records, including the name of the drug, daily doses, and dates of all outpatient prescriptions dispensed to eligible patients. These databases have been used extensively to research health outcomes and health services. [14] [15] [16] [17] [18] [19] [20] These databases were held securely in a linked, de-identified form at ICES and analyzed at the ICES Western site.
We used a combination of CIHI-DAD, NACRS, and ODB to identify patients who met the definition of medically intractable epilepsy and CIHI-DAD, OHIP, NACRS, and RPDB to define patient characteristics and baseline comorbidities and report patient outcomes. To define baseline comorbidities, we reviewed all health care records (inpatient and outpatient) in the 5 years prior to the diagnosis of medically intractable epilepsy. In some cases the look-back period included a time frame prior to the transition from ICD-9 to ICD-10 coding (prior to April 1, 2002) . Therefore, whenever possible we used database codes that had been validated with chart review or established coding algorithms included in previous administrative database studies.
Identification of patients with medically intractable epilepsy. Identification of patients with medically intractable epilepsy is detailed in figure e-1 on the Neurology ® Web site at Neurology.org. The ILAE defines medically intractable epilepsy as a continuation of seizures despite the use of 2 adequate trials of seizure drugs. In this study, we accrued patients 18 years of age and older meeting the definition of medically intractable epilepsy over a 10-year period as follows. We first identified all patients with a documented seizure episode between January 1, 2001, and December 31, 2010. Seizures were identified through emergency room and hospitalization records using validated ICD-9 and ICD-10 codes. 21, 22 We then excluded records with invalid or inaccurate information and all patients younger than 18 years at the time of the seizure. We further excluded patients with a diagnosis of a brain tumor in the previous 5 years as occasionally patients with brain tumors undergo surgery because of focal neurologic deficits, the tumor's nature (e.g., malignancy), and not because their seizures are refractory to medical treatment. We also excluded patients who had a previous epilepsy surgery dating back to the earliest available health care records in Ontario (July 1, 1991). This was done to eliminate potential preclusion of surgery as subsequent treatment. Since the definition of medically intractable epilepsy requires the knowledge of prior seizure drug use, we further restricted this group to patients who were eligible for prescription drug coverage in the previous 2 years by ensuring that patients had filled at least one prescription with the ODB in each of the 2 years prior to the index seizure. Finally, we excluded patients who did not fill at least 2 different seizure drugs, each with a cumulative day supply of at least 6 months in the 2 years prior to the index seizure (as these patients did not meet the definition of medically intractable epilepsy). The final study cohort was established by restricting to the first seizure episode per patient; this date served as the index date and the start time for follow-up. Patients who turned 18 during the study period were eligible for entry in the study as long as they had a seizure event after age 18 years.
Outcomes. Our primary outcome included the assessment for epilepsy surgery, or procedure for epilepsy surgery in the 2 years following the index date, identified using billing codes. In addition to the epilepsy surgery procedure, we also considered the placement of intracranial electrodes as this indicated that the patient was assessed for epilepsy surgery, but did not receive it because he or she was not a candidate for the procedure. Secondary outcomes investigated during the same 2-year follow-up window were any neurologic consults by a neurologist, subsequent emergency visits for seizures, and all-cause mortality.
Statistical analysis. Using t tests for continuous variables and x 2 tests for categorical variables, we compared baseline characteristics of the patients with medically intractable epilepsy who later underwent epilepsy surgery to baseline characteristics of those who did not have surgery. We used multivariable logbinomial regression to present relative risk estimates of possible predictors for epilepsy surgery. Predictors included the patient characteristics of age; sex; location of residence (urban or rural); the Ontario marginalization index, 23 based on Canadian census dissemination areas (49,153 in total) for residential instability, deprivation, dependency, and ethnic concentration 23 ; and the Charlson Comorbidity Index, a measure of comorbidity. 24 To compare the mortality rate between medically intractable patients and the general population, we matched each patient to four community controls on age, sex, location (rural/urban), and neighborhood income quintile. We presented survival differences using Kaplan-Meier estimates and used conditional logistic regression to estimate the odds ratio. All analyses were conducted using 2-sided tests with p value cutoffs of 0.05. Analyses were conducted using SAS statistical software version 9.3 (Cary, NC, USA). (table 3) . DISCUSSION In this study, we identified that a small percentage of patients with medically intractable epilepsy received epilepsy surgery treatment. Even though consideration for epilepsy surgery is the recommended standard of care for patients with medically intractable epilepsy, that treatment is not being adequately utilized.
RESULTS
These findings are intriguing given the strong evidence in the literature favoring this treatment. 6, 8 A possible explanation includes lack of awareness among general practitioners or neurologists, which has not been explored. Most likely there is a combination of lack of knowledge, misconceptions about the risks vs benefits of the procedure, as well as lack of education in medical schools and residency programs. Furthermore, patients and families may also lack awareness of the effectiveness and low risk of morbidity of epilepsy surgery. Another explanation may relate to the small number of epilepsy programs with the capability to perform a comprehensive investigation in order to determine if the patient is a surgical candidate and subsequently perform the surgical procedure. In Ontario, by the time this study was finished, there were only 2 programs with infrastructure and personnel to perform epilepsy surgery in adults and 2 in children, with a total 18 beds with video-EEG capability. They are located in the cities of London and Toronto, in the southwestern portion of the province. Other major cities in the province like Ottawa do not have video-EEG monitoring beds or epilepsy surgery programs. However, isolated reports, letters, and commentaries in medical journals indicate that lack of infrastructure does not appear to be the cause for the low number of epilepsy surgeries. 5, 25 In the United States, trends of epilepsy surgery have also been published and the situation is similar. 26 We thought the situation might be different in a society with a universal health system like Ontario, but our findings do not support that.
The main limitations of the study reside in its retrospective nature as well as the limited access we had to identify all patients with medically intractable epilepsy in Ontario. Information obtained from the drug dispensing database only represented a portion of the overall Ontario population. The ODB provides governmentsponsored drug coverage to all patients older than 65 years, as well as those under 65 years who have high drug costs relative to their income, or receive social assistance due to unemployment or a medical disability. Even though not all patients with epilepsy receive ODB coverage we suspect that a large proportion do. This is likely because epilepsy affects individuals' performance at work; additionally, ongoing seizures would render them ineligible to drive or perform risky jobs. While developing our cohort, we identified that 55% adult seizure patients were not covered under ODB; however, not all these patients would have met the clinical definition of epilepsy or required seizure medications. This is thus an overestimate of the proportion of medically intractable epilepsy patients who were not captured in this study.
The use of administrative databases in research allows the inclusion of population-based samples, increasing statistical power as well as maximizing generalizability of findings. It also allows the recording of health services use in a contemporary manner, avoiding the problems associated with imperfect recall, nonresponse, or reporting bias. These represent the major strengths of their use; however, limitations related to their use are important to note. These databases rely on coding to identify diagnoses and procedures; coding is often completed by trained coders based on information entered on the patient's chart. Diagnostic coding is thus often underrepresented as apparent diagnoses may not be noted by clinicians on patient charts. This may impact the magnitude of reported comorbidities. Furthermore, since these databases were created for administrative and financial purposes, they may lack details on important clinical factors such as height, weight, blood pressure readings, and smoking status. 27, 28 The time window of this study included the transition from ICD-9 to ICD-10 in Canada. Validation studies for both ICD-9 and ICD-10 versions of seizure codes report similar operating characteristics. 22 Furthermore, we observed that the annual number of patients with medically intractable epilepsy was consistent throughout the study period, suggesting no obvious difference in seizure case definitions due to the changes in coding practices.
We found that only 2.2% of those with medically intractable epilepsy underwent prolonged video-EEG, and half of them underwent epilepsy surgery. Unfortunately, we could not determine why some of those who did have a presurgical evaluation with video-EEG did not have surgery. Reasons could have been multifocal or generalized epilepsy, nonepileptic events, or patient's own preference.
Another issue is the fact that we did not include patients who had any type of neurostimulator implanted for the management of epilepsy, particularly the vagus nerve stimulator (VNS). A review of the physicians' billing database revealed that only 14 patients received a peripheral nerve stimulation device (which is how VNS is coded in OHIP). That may have included other types of stimulators not used for epilepsy (like a spinal cord stimulator for pain management). Furthermore, the provincial budget for neurostimulators for epilepsy was almost nonexistent before 2011, and thalamic or hippocampal stimulators were approved for clinical use only after 2011.
Another interesting observation of the study is the high percentage of patients going to the emergency room because of seizures within the first 2 years after they were identified as medically intractable. This group of patients produces a high cost to the health system. 29 Furthermore, there is a high percentage of death among middle-aged patients with medically intractable epilepsy; in this study, we could not reliably determine the cause of death. But the proportion of deaths among those with medically intractable epilepsy was substantially higher than in matched controls from the community.
Medically intractable epilepsy is a condition that impairs patient health and quality of life. Most patients with epilepsy are young, and cannot join the workforce because of frequent seizures. Furthermore, medically intractable epilepsy is associated with increased mortality and high societal costs. Epilepsy surgery may be an effective treatment for some patients, but is currently underutilized even in a health system with universal access.
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